Endocyte Balance Sheet - Quarterly (NASDAQ:ECYT)

Add to My Stocks
$16.5 $0.76 (4.4%) ECYT stock closing price Jul 16, 2018 (Closing)

The financial analysis of a company involves interpreting the income statement, balance sheet and cash flow statements of the company to draw insights like we've done in our Endocyte stock analysis. Financial strength can be guaged by performing Endocyte stock analysis and by analyzing the balance sheet. Good quarterly results indicate a company's strong financial performance. Its important to check all financial statements including the balance sheet. Endocyte balance sheet as at the end of 2018 Q1 indicates an asset turnover ratio of 0 and debt to equity ratio of 0. Also check Endocyte revenue and Endocyte operating cash flow for the same period.

View and download Endocyte quarterly results to get the balance sheet details for the latest 40 quarters data.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q4
Marketable Securities83.29M78.91M55.9M53.46M93.9M106.97M111.98M128.02M123.17M158.16M
Raw Materials----------
Work In Progress----------
Finished Goods----------
Notes Receivable----------
Other Current Assets1.43M-1.28M-1.8M1.99M1.8M1.22M1.5M1.26M
Total Current Assets
Property Plant & Equipment-7.36M---8.45M---7.75M
Accumulated Depreciation-5.18M---5.25M---4.35M
Net Property Plant & Equipment
Investment & Advances----------
Other Non-Current Assets----------
Deferred Charges----------
Deposits & Other Assets----------
Total Assets
Notes Payable----------
Accounts Payable1.41M--1.23M1.54M1.38M1.51M1.36M1.24M1.26M
Current Portion Long-Term Debt----------
Current Portion Capital Leases----------
Accrued Expenses3.19M4.16M3.95M4M3.36M4.18M3.03M3.18M3.09M4.92M
Income Taxes Payable----------
Other Current Liabilities----------
Total Current Liabilities
Deferred Taxes/Income----------
Convertible Debt----------
Long-Term Debt----------
Non-Current Capital Leases----------
Other Long-Term Liabilities----------
Total Liabilities
Minority Interest----------
Preferred Stock----------
Common Stock Net----------
Capital Surplus488.92M404.45M402.1M393.06M392.09M390.76M389.11M387.75M383.18M381.11M
Retained Earnings-317.21M-308.95M-300.39M-277.12M-265.37M-253.62M-242.55M-233.85M-219.88M-209.73M
Treasury Stock----------
Other Liabilities-0.07M-0.06M--0.03M-0.05M-0.04M----0.07M
Shareholders Equity171.7M95.48M101.75M115.94M126.7M137.14M146.63M154.04M163.37M171.34M
Total Liabilities & Shareholders Equity176.67M100.76M106.84M121.94M132.38M143.49M151.98M159.4M168.54M178.38M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Apart from balance sheet items, an investor would do well to keep track of the Endocyte stock price by looking at Endocyte historical stock prices. One can compare PE with industry average by looking at the Endocyte PE ratio chart. The common balance sheet items are:

  • Assets: Anything that the Endocyte company owns and is a part of its books. Assets can be of three types: fixed, current and other assets which includes intangibles, advances. Internet companies typically don't have a lot of assets as there is not much investment in say machinery, equipment etc. Endocyte had total assets of $176.67M.
  • Liabilities or obligations comprise of current liabilities that include short term loans, amounts payable to suppliers, or any other outstanding payments including long term liabilities that take into account long term loans for funding large projects. The total liabilities for Endocyte is $4.97M. Shareholders equity comes under liabilities as it is money the company owes the holders of ECYT stock.

Endocyte Balance Sheet - Key Ratios

Current ratio
Debt to equity ratio
Asset turnover ratio
Receivables turnover
Price to book ratio